Diltiazem market to see 12.3 % CAGR to 2028
Posted by kartik joshi on October 4th, 2022
Diltiazem Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product type and application,” the market is projected to reach US$ 832.51 million by 2028 from US$ 369.95 million in 2021; it is expected to grow at a CAGR of 12.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Early during the pandemic, chloroquine and hydroxychloroquine were promoted as efficacious treatments against COVID-19. But a recent report dismissed both drugs showing that they suppress viral growth in the epithelial kidney cell line Vero E6 but not in the relevant epithelial lung Calu-3 cells. Remdesivir initially developed for Ebola treatment, is presently the only antiviral therapy used to effectively treat COVID-19 patients and was shown to improve symptoms in 68% of treated patients in clinical trials. However, with only one efficacious antiviral therapy on the market, there remains a need to identify and provide additional drugs to treat COVID-19 patients. Given the current pandemic and the need for practicality, these drugs should ideally be FDA approved so they can be rapidly repurposed for COVID-19 treatment. SARS-CoV requires Ca2+ ions for host cell entrance and based on the connection between SARS-CoV and SARS-CoV-2, it is very likely that the exact necessities exist for both viruses. Moreover, as per the recent report of bioRxiv published in July 2020, there is evidence that calcium channel blockers (CCB) inhibit viral infections at the cell entry-level. Therefore, treatment with verapamil or diltiazem inhibits viral infection.
Sample Report Copy from Here
Glenmark Pharmaceuticals and Mylan N.V - Notable Market Players in Diltiazem Market
Diltiazem is used to treat high blood pressure and to control angina (chest pain). Diltiazem is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels, so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart.
Market leaders operating in the market have undertaken various organic growth strategies in the Diltiazem market. The Diltiazem market majorly consists of the players Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag),Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the Diltiazem market:
Email Id: email@example.com
Like it? Share it!
About the Authorkartik joshi
Joined: September 27th, 2022
Articles Posted: 87
More by this author